Jan de Vries
Dutch National, in La Jolla (CA) USA, has been a board member of Cassiopea since 2015. He is also the Chairman of Artax Inc, Board member and CEO of AIMM Therapeutics BV, Member of the Scientific Advisory Board of Anaptys Inc. From 2008 to 2010 he was the head of Novartis Institutes for Biomedical Research, from 1997 to 2008 he was the Head of Novartis Autoimmunity, Transplantation and Inflammation, from 1989 to 1997 Director of Human Immunology Department at DNAX Research Institute of Molecular and Cellular Biology (Schering Plough, now Merck). From 1985 to 1989 he was Co-director of the Schering Plough Laboratory for Immunological Research, from 1978 to 1985 he was Chairman of the Immunology Department at the Netherland Cancer Institute which he joined in 1969. He brought 15 different compounds to clinical trials three of which (Elidel; psoriasis and atopic dermatitis, Gilenyya and Ilaris) are in the market and one for actinic keratosis that was licensed out. Patents were granted for 20 of the products he worked on. He has published more than 220 papers in scientific journals and written 80 book chapters and received numerous awards and honors including the International Bekales Prize for Leukemia Research, the S. Johansson Lecture and Medal, the C. Praussnitz Prize and the Novartis innovation price in 2006. Dr de Vries has a PhD in immunology form the University of Amsterdam and an MSc degree in Biology/Biochemistry from the University of Utrecht.